Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd155-hIi-HBV vaccine
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAd155-hIi-HBV vaccine is an investigational recombinant chimpanzee adenovirus type 155-based viral vector vaccine developed by GSK for the treatment of chronic hepatitis B (CHB). The vaccine construct utilizes a replication-defective chimpanzee adenovirus serotype 155 (ChAd155) backbone encoding two hepatitis B virus (HBV) antigens: the truncated core nucleocapsid protein antigen (HBc) and the full-length small surface antigen (HBs). To enhance antigen presentation and stimulate a robust T-cell and antibody immune response, the human MHC class II-associated invariant chain (hIi, CD74, p35 isoform) is fused to the HBc protein. ChAd155-hIi-HBV has been evaluated in clinical trials as the 'prime' component of a heterologous prime-boost immunotherapy regimen (followed by MVA-HBV and adjuvanted protein vaccines) and in sequential combination with the antisense oligonucleotide bepirovirsen.
- Other names
- ChAd155-hli-HBV vaccineChAd-155-hli-HBV vaccineChAd 155-hli-HBV vaccineChimpanzee adenovirus HBV vaccine
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on ChAd155-hIi-HBV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd155-hIi-HBV vaccine.